Developer docs
API playgroundTry for free, no card

Search company profiles

Calon Cardio-Technology

Full company profile

uuid000a1c6

Namestring
Calon Cardio-Technology
Legal namestring
Calon Cardio-Technology
Websiteurl
caloncardio.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Calon Cardio-Technology was a Swansea, Wales-based medical device company developing next-generation implantable micro-pumps intended for the treatment of heart failure. Founded in 2007 (per firmographics) and operating with a small team in the 11-50 headcount band, the company targeted the cardiac assist device market, which third-party sources projected to reach $3.76 billion by 2030 at a 10.4% CAGR. Its core product was an implantable micro-pump designed to support cardiac function in heart failure patients, and the company was led by founder Stephen Westaby, a recognized figure in cardiac surgery and mechanical circulatory support research. The technology description in available sources covers cardiac assist device mechanics only; no AI, software platform, or digital health components are disclosed.

Calon's business model was that of an R&D-stage, pre-revenue medtech: the company developed its pump technology with a view to eventual regulatory approval and commercialization rather than current-period sales. It raised approximately £3.5m in disclosed equity and debt funding, primarily from the Development Bank of Wales (which held a 9% stake at administration) and its predecessor Finance Wales, with additional capital from Longbow Capital and a 2015 SyndicateRoom-led round of approximately $1.9m. No commercial products, pricing models, customer relationships, or recurring revenue streams are disclosed in the available data, consistent with a pre-commercial development posture.

In mid-2026, after a proposed £39m acquisition by AIM-listed Ashington Innovation collapsed and a planned $2.6m funding injection from a US-based lender failed to clear UK Anti-Money Laundering compliance checks, Calon entered administration. By February 2027 the company was being liquidated with a £5.4m deficit to creditors including HMRC, Swansea Council and Swansea University. 17 former employees were owed wages and holiday pay as preferential creditors, and no buyer or company voluntary arrangement emerged to continue the business; the operating status is recorded as closed.

Short descriptiontext

Calon Cardio-Technology was a Swansea-based medtech firm developing next-generation implantable micro-pumps for heart failure treatment; it entered administration in 2026 and was being liquidated with a £5.4m deficit to creditors.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSwansea, United Kingdom
HQ citystring
Swansea
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac assist devices, heart failure treatment, implantable medical devices, ventricular assist devices, cardiovascular medical technology
Industry2 codes
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Assist Devices
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Calon Cardio-Technology is developing a next-generation implantable micro-pump intended for the treatment of heart failure. The company operated as a Swansea-based medtech firm focused on cardiac assist device technology for the cardiovascular/heart failure treatment market.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Implantable Micro-Pump for Heart Failure
CategoryCardiac Assist Devices
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Builds the world's smallest heart pump (Elevate) for circulatory support; a venture-stage peer pursuing miniaturized cardiac assist technology.

TypeBroad incumbent
Description

Maker of the Impella percutaneous heart pump and a leader in mechanical circulatory support; directly relevant as the dominant player in the cardiac assist pump category Calon targeted.

TypeEmerging player
Description

Developing a rotary total artificial heart using maglev pump technology; an emerging mechanical circulatory support peer for end-stage heart failure.

TypeEmerging player
Description

European company developing an implantable flow maker (ICOMS) for heart failure; comparable emerging implantable cardiac assist developer.

TypeEmerging player
Description

French startup developing a novel implantable LVAD with a wave-membrane pump; a close emerging-stage analogue pursuing next-generation implantable heart pumps like Calon.

6Evaheart
TypeEmerging player
Description

Develops an implantable centrifugal LVAD for advanced heart failure; a niche peer in the implantable cardiac pump segment Calon pursued.

7CARMAT
TypeEmerging player
Description

Maker of the Aeson total artificial heart for advanced heart failure; a comparable European implantable cardiac device company addressing the same end-stage patient population.

8Berlin Heart
TypeRegional player
Description

European manufacturer of ventricular assist devices (EXCOR, INCOR) for heart failure; a comparable circulatory support device maker primarily serving European markets.

TypeEmerging player
Description

Developing a catheter-deployed intra-aortic micro-pump for heart failure, directly comparable to Calon's micro-pump approach for circulatory support.

10Abbott (HeartMate)
TypeBroad incumbent
Description

HeartMate LVAD is the market-leading implantable ventricular assist device for heart failure, the exact device class Calon's micro-pump aimed to compete in.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Calon Cardio-Technology

Cardiac Assist Devicescaloncardio.com

Calon Cardio-Technology was a Swansea-based medtech firm developing next-generation implantable micro-pumps for heart failure treatment; it entered administration in 2026 and was being liquidated with a £5.4m deficit to creditors.

What Calon Cardio-Technology does

Calon Cardio-Technology was a Swansea, Wales-based medical device company developing next-generation implantable micro-pumps intended for the treatment of heart failure. Founded in 2007 (per firmographics) and operating with a small team in the 11-50 headcount band, the company targeted the cardiac assist device market, which third-party sources projected to reach $3.76 billion by 2030 at a 10.4% CAGR. Its core product was an implantable micro-pump designed to support cardiac function in heart failure patients, and the company was led by founder Stephen Westaby, a recognized figure in cardiac surgery and mechanical circulatory support research. The technology description in available sources covers cardiac assist device mechanics only; no AI, software platform, or digital health components are disclosed.

Calon's business model was that of an R&D-stage, pre-revenue medtech: the company developed its pump technology with a view to eventual regulatory approval and commercialization rather than current-period sales. It raised approximately £3.5m in disclosed equity and debt funding, primarily from the Development Bank of Wales (which held a 9% stake at administration) and its predecessor Finance Wales, with additional capital from Longbow Capital and a 2015 SyndicateRoom-led round of approximately $1.9m. No commercial products, pricing models, customer relationships, or recurring revenue streams are disclosed in the available data, consistent with a pre-commercial development posture.

In mid-2026, after a proposed £39m acquisition by AIM-listed Ashington Innovation collapsed and a planned $2.6m funding injection from a US-based lender failed to clear UK Anti-Money Laundering compliance checks, Calon entered administration. By February 2027 the company was being liquidated with a £5.4m deficit to creditors including HMRC, Swansea Council and Swansea University. 17 former employees were owed wages and holiday pay as preferential creditors, and no buyer or company voluntary arrangement emerged to continue the business; the operating status is recorded as closed.

Calon Cardio-Technology firmographics

Firmographics
Name
Calon Cardio-Technology
Legal name
Calon Cardio-Technology
Website
https://caloncardio.com
Company type
Private
Founded year
2007
Operating status
Closed
Headcount range
1–10 employees
Short description
Calon Cardio-Technology was a Swansea-based medtech firm developing next-generation implantable micro-pumps for heart failure treatment; it entered administration in 2026 and was being liquidated with a £5.4m deficit to creditors.
Ownership category
akta.pro rank

Calon Cardio-Technology industry classification

Industry
Product category
Cardiac Assist Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cardiac assist devices
  • Heart failure treatment
  • Implantable medical devices
  • Ventricular assist devices
  • Cardiovascular medical technology

Where Calon Cardio-Technology is headquartered

Location

Headquarters

HQ city
Swansea
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Calon Cardio-Technology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Calon Cardio-Technology product offering

Product offering

Core offering

Calon Cardio-Technology is developing a next-generation implantable micro-pump intended for the treatment of heart failure. The company operated as a Swansea-based medtech firm focused on cardiac assist device technology for the cardiovascular/heart failure treatment market.

Differentiator

Problem solved

Functional benefit

Products and services

  • Implantable Micro-Pump for Heart Failure

Companies that use Calon Cardio-Technology

Customer profile

Ideal customer profiles1 record

Calon Cardio-Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Calon Cardio-Technology partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights2 records

Calon Cardio-Technology competitors and assessment

Company assessment

Emerging players

  • Magenta Medical: Builds the world's smallest heart pump (Elevate) for circulatory support; a venture-stage peer pursuing miniaturized cardiac assist technology.
  • BiVACOR: Developing a rotary total artificial heart using maglev pump technology; an emerging mechanical circulatory support peer for end-stage heart failure.
  • FineHeart: European company developing an implantable flow maker (ICOMS) for heart failure; comparable emerging implantable cardiac assist developer.
  • CorWave: French startup developing a novel implantable LVAD with a wave-membrane pump; a close emerging-stage analogue pursuing next-generation implantable heart pumps like Calon.
  • Evaheart: Develops an implantable centrifugal LVAD for advanced heart failure; a niche peer in the implantable cardiac pump segment Calon pursued.
  • CARMAT: Maker of the Aeson total artificial heart for advanced heart failure; a comparable European implantable cardiac device company addressing the same end-stage patient population.
  • Procyrion (Aortix): Developing a catheter-deployed intra-aortic micro-pump for heart failure, directly comparable to Calon's micro-pump approach for circulatory support.

Broad incumbents

  • Abiomed: Maker of the Impella percutaneous heart pump and a leader in mechanical circulatory support; directly relevant as the dominant player in the cardiac assist pump category Calon targeted.
  • Abbott (HeartMate): HeartMate LVAD is the market-leading implantable ventricular assist device for heart failure, the exact device class Calon's micro-pump aimed to compete in.

Regional players

  • Berlin Heart: European manufacturer of ventricular assist devices (EXCOR, INCOR) for heart failure; a comparable circulatory support device maker primarily serving European markets.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key highlights5 records

Customer concentration

Calon Cardio-Technology social profiles

Digital presence

Calon Cardio-Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Calon Cardio-Technology leadership team

Management profile

Number of profiles

Profiles1 record

Calon Cardio-Technology funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Calon Cardio-Technology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Calon Cardio-Technology

What does Calon Cardio-Technology do?

Calon Cardio-Technology is developing a next-generation implantable micro-pump intended for the treatment of heart failure. The company operated as a Swansea-based medtech firm focused on cardiac assist device technology for the cardiovascular/heart failure treatment market.

Is Calon Cardio-Technology a public or private company?

Calon Cardio-Technology is a private company. It is classified as venture growth investor backed and is currently closed.

When was Calon Cardio-Technology founded?

Calon Cardio-Technology was founded in 2007. It employs 1 to 10 people.

Where is Calon Cardio-Technology based?

Calon Cardio-Technology is headquartered in Swansea, United Kingdom, in the Europe region.

Who are Calon Cardio-Technology's main competitors?

Emerging players on record are Magenta Medical, BiVACOR, FineHeart, CorWave, Evaheart, CARMAT and Procyrion (Aortix). Broad incumbents are Abiomed and Abbott (HeartMate). Berlin Heart is listed as a regional player.

Does Calon Cardio-Technology have an API?

No public API is recorded for Calon Cardio-Technology.

What industry is Calon Cardio-Technology in?

Calon Cardio-Technology's product category is Cardiac Assist Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business LiveSwansea medtech firm Calon Cardio-Technology being liquidated owing creditors millionsSwansea-based medtech firm Calon Cardio-Technology is being liquidated with a deficit to creditors estimated at £5.4m, after failed efforts to rescue the company through acquisition or a company voluntary arrangement following its entry into administration last summer. The Development Bank of Wales, which invested £3.5m through debt and equity alongside predecessor Finance Wales and held a 9% stake at administration, is among the major creditors alongside HMRC, Swansea Council, and Swansea University, with preferential creditors (including 17 former employees owed wages and holiday pay) expected to receive approximately £21,000 from asset realizations. A proposed £39m acquisition by AIM-listed Ashington Innovation fell through, and a potential $2.6m funding transfer from an identified US-based lender also failed to materialize amid concerns over compliance with UK Anti-Money Laundering Regulations.PR NewswireBreakthrough in Device Therapy for Patients with Late-Stage Heart DiseaseCalon Cardio-Technology Ltd and Leviticus Cardio Ltd have successfully completed a 60-day in-vivo pre-clinical study of a fully implantable ventricular assist device (FiVAD) that combines both companies' technologies, eliminating the need for external power cables that have traditionally limited VAD therapy. The study was conducted at the Catholic University of Leuven in Belgium and demonstrated that patients can go a full day without any external connections, with recharging accomplished simply by wearing a light belt overnight. The companies stated the breakthrough could make VAD therapy a routine treatment option and potentially supersede cardiac transplant as the preferred intervention for advanced heart failure patients.